Clinical Efficacy Of 2% Rebamipide In Patients With Video Display Terminal-Associated Dry Eye Disease: A Prospective, Randomized, Double-Blinded Study
Published 2024 - 42nd Congress of the ESCRS
Reference: PO943 | Type: Poster | DOI: 10.82333/tdqs-c425
Authors: Sang Beom Han* 1 , Yong Woo Lee 2
1Saevit Eye Hospital,Goyang,Korea, Republic Of, 2Ophthalmology,Kangwon National University Hospital,Chuncheon,Korea, Republic Of
Purpose
To compare the therapeutic effects of 2% rebamipide clear solution and 0.1% sodium hyaluronate eye drops in patients with visual display terminal (VDT)-related dry eye disease (DED).
Setting
: This was a prospective, double-blind, and randomized controlled study.
Methods
Patients with VDT-related DED who had not previously used other eye drops were recruited. They were randomly allocated to a 2% rebamipide eye drop (REB) group or a 0.1% sodium hyaluronate eye drop (HYA) group (four times a day for 4 weeks). The ocular surface disease index (OSDI) and dry eye questionnaire-5 (DEQ-5) were measured before and 4 weeks after the instillation of each drug, and DED parameters were examined using a Placido disk-tear film analyzer (Keratograph 5M, Oculus, Wetzlar, Germany). Fluorescein-stained tear break-up time (FBUT), corneal and conjunctival staining scores, and Schirmer 1 test results were measured.
Results
In each group, 28 eyes of 14 patients were included. There were no significant differences in DED symptom scores and signs before treatment between the two groups. The OSDI, DEQ-5, FBUT, and conjunctival erosion scores improved significantly in both groups after treatment compared to before treatment. In the REB group, corneal staining and bulbar nasal redness scores also improved significantly after treatment (P<0.001 and 0.036, respectively), whereas no significant differences were found in these parameters in the HYA group (P=0.326 and 0.118, respectively). Regarding the change in DED parameters after treatment, the REB group showed a significantly larger decrease in the corneal staining score than the HYA group (p=0.016).
Conclusions
A 2% rebamipide ophthalmic clear solution effectively improved the symptoms and signs in patients with VDT-related DED and was superior to 0.1% sodium hyaluronate ophthalmic solution in improving corneal epithelial damage, making it a safe and effective treatment option for VDT-related DED.